Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Multiple Myeloma Drugs Global Market Report 2025
Download Free Sample Buy Now
Global Multiple Myeloma Drugs Market Report 2025

Report Price : $4490.00

Pages :

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Multiple Myeloma Drugs Global Market Report 2025

By Drug Type (Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types), By Therapy (Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels), By End-User (Men, Women) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Multiple Myeloma Drugs Market Overview

• Multiple Myeloma Drugs market size has reached to $21.84 billion in 2024

• Expected to grow to $29.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%

• Growth Driver: Soaring Prevalence Of Hematological Cancer Fuels Expansion

• Market Trend: Janssen Biotech Introduced A Groundbreaking Car T-Cell Therapy

• North America was the largest region in 2024.

What Is Covered Under Multiple Myeloma Drugs Market?

Multiple myeloma drugs refer to medications utilized to treat multiple myeloma and cancer-impacting plasma cells (white blood cells found in the bone marrow). These drugs are employed to address bone-related issues such as myeloma, pamidronate (Aredia), and zoledronic acid (Zometa) in an individual.

The main multiple myeloma drugs are immunomodulatory, proteasome inhibitors, histone deacetylase inhibitors, monoclonal antibody drugs, steroids, and others. Targeted therapy is a type of cancer treatment that focuses on employing medications or chemicals to directly target molecules critical for cancer cell survival and proliferation and it is used in treating multiple myeloma to specifically target certain molecules (such as proteins) on or within cancer cells, where these chemicals aid in the transmission of signals that instruct cells to grow or divide. The various therapies are targeted therapy, biologic therapy, chemotherapy, and others that are distributed by different distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others, which are used by men and women.

Multiple Myeloma Drugs Market Size and growth rate 2025 to 2029: Graph

What Is The Multiple Myeloma Drugs Market Size 2025 And Growth Rate?

The multiple myeloma drugs market size has grown strongly in recent years. It will grow from $21.84 billion in 2024 to $23.03 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to improved diagnosis, clinical trials success, understanding of disease biology, healthcare infrastructure improvements, patient advocacy, and awareness

What Is The Multiple Myeloma Drugs Market Growth Forecast?

The multiple myeloma drugs market size is expected to see strong growth in the next few years. It will grow to $29.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to immunotherapy innovations, targeted therapies expansion, liquid biopsy applications, the emergence of car-t cell therapy, and biomarker discovery. Major trends in the forecast period include long-term survivorship focus, exploration of epigenetic therapies, expanded role of telemedicine, expanded access to novel therapies, and sustainability in myeloma care.

The forecast of 6.3% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. oncology clinics by increasing the cost of proteasome inhibitors and monoclonal antibodies sourced from Switzerland and Ireland, thereby delaying treatment regimens and elevating hematologic cancer care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Multiple Myeloma Drugs Market Segmented?

1) By Drug Type: Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types

2) By Therapy: Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Men, Women

Subsegments:

1) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide

2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib

3) By Histone Deacetylase Inhibitors: Panobinostat, Romidepsin

4) By Monoclonal Antibody Drugs: Daratumumab, Elotuzumab, Isatuximab

5) By Steroids: Dexamethasone, Prednisone

6) By Other Drug Types: Alkylating Agents, Antimetabolites, New Experimental Drugs

What Is Driving The Multiple Myeloma Drugs Market? Soaring Prevalence Of Hematological Cancer Fuels Expansion

The increasing prevalence of hematological cancer is expected to drive the growth of the multiple myeloma drugs market going forward. Hematological cancers start in blood-forming tissue, such as bone marrow, or immune system cells, such as leukemia, lymphoma, multiple myeloma, and others. Multiple myeloma medications are often used to treat various myeloma by killing and limiting the growth of cancer cells by decreasing the process of cell division by stimulating numerous enzymatic actions and assisting bones to stay strong and reducing pain in the weakening bone. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based health organization dedicated to eliminating cancer, there were approximately 59,610 newly diagnosed cases of leukemia and around 20,380 cases of acute myeloid leukemia (AML). Additionally, the total number of deaths attributed to leukemia amounted to 23,710. Therefore, the increasing prevalence of hematological cancer is driving the growth of multiple myeloma drugs industry.

What Is Driving The Multiple Myeloma Drugs Market? Biotechnology And Precision Medicine Propel Advancements In The Multiple Myeloma Drugs Market

The progress in biotechnology and precision medicine is expected to propel the growth of the multiple myeloma drugs market going forward. Biotechnology involves the application of biological systems, organisms, or derivatives to develop innovative products and technologies, while precision medicine is a personalized approach to healthcare that tailors medical treatment and interventions to individual characteristics such as genetics, molecular profile, and environmental factors for more targeted and effective outcomes. Biotechnology and precision medicine use multiple myeloma drugs by employing advanced genetic and molecular insights to identify targeted therapies tailored to individual patients, optimizing treatment effectiveness. For instance, in October 2022, according to estimates from the Personalized Medicine Coalition (PMC), a US-based non-profit healthcare organization, more than 75,000 genetic testing kits and 300 personalized treatments will be available for people suffering from a variety of cancers, hereditary uncommon disorders, and chronic and infectious diseases. Therefore, the progress in biotechnology and precision medicine drives the multiple myeloma drugs industry.

Who Are The Major Players In The Global Multiple Myeloma Drugs Market?

Major companies operating in the multiple myeloma drugs market include Pfizer Inc., Johnson & Johnson Pvt. Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG., Roche Holding AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc, Amgen Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company, Daiichi Sankyo Co. Ltd., Lonza Group AG, Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Biotest AG, Onyx Pharmaceuticals Inc., PharmaMar SA, Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., Oncopetides AB

What Are The Key Trends Of The Global Multiple Myeloma Drugs Market? Janssen Biotech Introduced A Groundbreaking Car T-Cell Therapy

Product innovation is a key trend gaining popularity in the multiple myeloma drugs market. Major companies operating in the multiple myeloma drugs market are focused on developing innovative products to strengthen their position and gain a competitive advantage. For instance, in March 2022, Janssen Biotech Inc., a Japan-based biotechnology company, received the United States Food and Drug Administration approval for Carvykti, a CAR T-Cell therapy (personalized immunotherapy) for multiple myeloma. CARVYKTI (ciltacabtagene autoleucel) is a genetically modified autologous cell-based product composed of T cells transduced ex vivo with a replication-incompetent lentiviral vector encoding an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) consisting of two single domain antibodies linked to a 4-1BB costimulatory domain and a CD3-zeta signaling domain. Patients who have received four or more lines of therapy, including treatment with three critical kinds of multiple myeloma medications (an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody), are eligible to receive it to treat relapsed conditions.

What Are The Key Trends Of The Global Multiple Myeloma Drugs Market? Kite Pharma And Arcellx Join Forces To Advance T-Cell Therapy For Relapsed Multiple Myeloma

Major companies operating in the multiple myeloma drug market are adopting a strategic partnership approach to co-develop and co-commercialize Arcellx's lead late-stage product candidate for the treatment of patients with multiple myeloma. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in December 2022, Kite Pharma, a company of Gilead Sciences Inc., a US-based pharmaceuticals company, partnered with Arcellx, a US-based biotechnology company. With this partnership, they aim to jointly develop and commercialize Arcellx's T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients. It utilizes the new D-Domain binder of Arcellx and contains autologous T cells genetically modified for targeting multiple myeloma.

Need data on a specific region in this market?
Request Regional Data

Multiple Myeloma Drugs Market Merger And Acquisition: Ipsen Acquires Epizyme To Strengthen Oncology Portfolio And Enhance Treatment Options

In August 2022, Ipsen France-based biopharmaceutical company acquired Epizyme, Inc. for an undisclosed amount. The acquisition aims to enhance Ipsen's oncology portfolio by integrating Epizyme's innovative therapies. This strategic deal allows Ipsen to leverage its established infrastructure and scientific expertise to deliver groundbreaking treatment options to underserved patients. Epizyme, Inc. is a US-based Biotechnology company that manufactures multiple myeloma drugs.

Regional Outlook For The Global Multiple Myeloma Drugs Market

North America was the largest region in the multiple myeloma drugs market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Multiple Myeloma Drugs Market?

The multiple myeloma drugs market consists of revenues earned by entities by providing various therapies such radiation therapy, bone-marrow transplant, surgery and stem-cell transplant. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiple myeloma drug market also includes sales of nuclear export inhibitors, bispecific T cell engager (BiTE), bisphosphonates, and alkylating agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Multiple Myeloma Drugs Industry?

The multiple myeloma drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the multiple myeloma drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Multiple Myeloma Drugs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $23.03 billion
Revenue Forecast In 2034 $29.44 billion
Growth Rate CAGR of 6.3% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Type: Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types
2) By Therapy: Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End-User: Men, Women Subsegments: 1) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide
2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib
3) By Histone Deacetylase Inhibitors: Panobinostat, Romidepsin
4) By Monoclonal Antibody Drugs: Daratumumab, Elotuzumab, Isatuximab
5) By Steroids: Dexamethasone, Prednisone 6) By Other Drug Types: Alkylating Agents, Antimetabolites, New Experimental Drugs
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Johnson & Johnson Pvt. Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG., Roche Holding AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc, Amgen Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company, Daiichi Sankyo Co. Ltd., Lonza Group AG, Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Biotest AG, Onyx Pharmaceuticals Inc., PharmaMar SA, Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., Oncopetides AB
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Multiple Myeloma Drugs Market Characteristics

3. Multiple Myeloma Drugs Market Trends And Strategies

4. Multiple Myeloma Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Multiple Myeloma Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Multiple Myeloma Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Multiple Myeloma Drugs Market Growth Rate Analysis

5.4. Global Multiple Myeloma Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Multiple Myeloma Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Multiple Myeloma Drugs Total Addressable Market (TAM)

6. Multiple Myeloma Drugs Market Segmentation

6.1. Global Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Immunomodulatory Drugs

Proteasome Inhibitors

Histone Deacetylase Inhibitors

Monoclonal Antibody Drugs

Steroids

Other Drug Types

6.2. Global Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Targeted Therapy

Biologic Therapy

Chemotherapy

Other Therapies

6.3. Global Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Other Distribution Channels

6.4. Global Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Men

Women

6.5. Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Immunomodulatory Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Lenalidomide

Thalidomide

Pomalidomide

6.6. Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Proteasome Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Bortezomib

Carfilzomib

Ixazomib

6.7. Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Histone Deacetylase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Panobinostat

Romidepsin

6.8. Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Monoclonal Antibody Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Daratumumab

Elotuzumab

Isatuximab

6.9. Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Dexamethasone

Prednisone

6.10. Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Alkylating Agents

Antimetabolites

New Experimental Drugs

7. Multiple Myeloma Drugs Market Regional And Country Analysis

7.1. Global Multiple Myeloma Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Multiple Myeloma Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Multiple Myeloma Drugs Market

8.1. Asia-Pacific Multiple Myeloma Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Multiple Myeloma Drugs Market

9.1. China Multiple Myeloma Drugs Market Overview

9.2. China Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Multiple Myeloma Drugs Market

10.1. India Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Multiple Myeloma Drugs Market

11.1. Japan Multiple Myeloma Drugs Market Overview

11.2. Japan Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Multiple Myeloma Drugs Market

12.1. Australia Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Multiple Myeloma Drugs Market

13.1. Indonesia Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Multiple Myeloma Drugs Market

14.1. South Korea Multiple Myeloma Drugs Market Overview

14.2. South Korea Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Multiple Myeloma Drugs Market

15.1. Western Europe Multiple Myeloma Drugs Market Overview

15.2. Western Europe Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Multiple Myeloma Drugs Market

16.1. UK Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Multiple Myeloma Drugs Market

17.1. Germany Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Multiple Myeloma Drugs Market

18.1. France Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Multiple Myeloma Drugs Market

19.1. Italy Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Multiple Myeloma Drugs Market

20.1. Spain Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Multiple Myeloma Drugs Market

21.1. Eastern Europe Multiple Myeloma Drugs Market Overview

21.2. Eastern Europe Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Multiple Myeloma Drugs Market

22.1. Russia Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Multiple Myeloma Drugs Market

23.1. North America Multiple Myeloma Drugs Market Overview

23.2. North America Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Multiple Myeloma Drugs Market

24.1. USA Multiple Myeloma Drugs Market Overview

24.2. USA Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Multiple Myeloma Drugs Market

25.1. Canada Multiple Myeloma Drugs Market Overview

25.2. Canada Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Multiple Myeloma Drugs Market

26.1. South America Multiple Myeloma Drugs Market Overview

26.2. South America Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Multiple Myeloma Drugs Market

27.1. Brazil Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Multiple Myeloma Drugs Market

28.1. Middle East Multiple Myeloma Drugs Market Overview

28.2. Middle East Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Multiple Myeloma Drugs Market

29.1. Africa Multiple Myeloma Drugs Market Overview

29.2. Africa Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Multiple Myeloma Drugs Market Competitive Landscape And Company Profiles

30.1. Multiple Myeloma Drugs Market Competitive Landscape

30.2. Multiple Myeloma Drugs Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Pvt. Ltd Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Bayer AG. Overview, Products and Services, Strategy and Financial Analysis

31. Multiple Myeloma Drugs Market Other Major And Innovative Companies

31.1. Roche Holding AG

31.2. Novartis AG

31.3. Sanofi S.A.

31.4. Bristol-Myers Squibb Company

31.5. GlaxoSmithKline Plc

31.6. Takeda Pharmaceutical Company Limited

31.7. Eli Lilly and Company

31.8. Kite Pharma Inc

31.9. Amgen Inc.

31.10. AstraZeneca plc

31.11. Teva Pharmaceutical Industries Ltd.

31.12. Regeneron Pharmaceuticals Inc.

31.13. Daiichi Sankyo Company

31.14. Lonza Group AG

31.15. Cipla Ltd.

32. Global Multiple Myeloma Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multiple Myeloma Drugs Market

34. Recent Developments In The Multiple Myeloma Drugs Market

35. Multiple Myeloma Drugs Market High Potential Countries, Segments and Strategies

35.1 Multiple Myeloma Drugs Market In 2029 - Countries Offering Most New Opportunities

35.2 Multiple Myeloma Drugs Market In 2029 - Segments Offering Most New Opportunities

35.3 Multiple Myeloma Drugs Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Immunomodulatory Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Proteasome Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Histone Deacetylase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Monoclonal Antibody Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Multiple Myeloma Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Multiple Myeloma Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Asia-Pacific, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: China, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: India, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Japan, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Australia, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Indonesia, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: South Korea, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Western Europe, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: UK, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Germany, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: France, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Italy, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Spain, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Eastern Europe, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Russia, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: North America, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: USA, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Canada, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: South America, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Brazil, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Middle East, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Africa, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: Pfizer Inc. Financial Performance
  • Table 82: Johnson & Johnson Pvt. Ltd Financial Performance
  • Table 83: Merck & Co. Inc. Financial Performance
  • Table 84: AbbVie Inc. Financial Performance
  • Table 85: Bayer AG. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Immunomodulatory Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Proteasome Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Histone Deacetylase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Monoclonal Antibody Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Multiple Myeloma Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Multiple Myeloma Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Multiple Myeloma Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Asia-Pacific, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: China, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: India, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Japan, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Australia, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Indonesia, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: South Korea, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Western Europe, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: UK, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Germany, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: France, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Italy, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Spain, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Eastern Europe, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Russia, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: North America, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: USA, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Canada, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: South America, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Brazil, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Middle East, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Africa, Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: Pfizer Inc. Financial Performance
  • Figure 82: Johnson & Johnson Pvt. Ltd Financial Performance
  • Figure 83: Merck & Co. Inc. Financial Performance
  • Figure 84: AbbVie Inc. Financial Performance
  • Figure 85: Bayer AG. Financial Performance

2025 Over-The-Counter (OTC) Diet Products Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Read More About 2025 Over-The-Counter (OTC) Diet Products Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Parathyroid Disease Treatment Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Parathyroid Disease Treatment Market Revenue Outlook: Strategic Insights and Forecast to 2029

Industry Forecast: PCSK9 Inhibitor Market to Generate $6.87 Billion Revenue by 2029

Read More About Industry Forecast: PCSK9 Inhibitor Market to Generate $6.87 Billion Revenue by 2029

CAGR of 5.4% Projected for Pediatric Asthma Treatment Market From 2025 to 2029

Read More About CAGR of 5.4% Projected for Pediatric Asthma Treatment Market From 2025 to 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Multiple Myeloma Drugs Global Market Report 2025 – By Drug Type (Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types), By Therapy (Targeted...

View Report

Multiple Myeloma Global Market Report 2025 – By Treatment (Medications, Radiation Therapy, Stem Cell Transplant, Other Treatments), By Diagnosis (Blood Tests, Bone Marrow Biopsy, Urine Tests, Imaging Tests), By Disease T...

View Report

Myeloproliferative Disorders Drugs Global Market Report 2025 – By Type (Primary Myelofibrosis, Polycythemia Vera (PV), Essential Thrombocythemia (ET), Chronic Eosinophilic Leukemia Or Hyper eosinophilic Syndrome (HES), S...

View Report

Myelodysplastic Syndrome Drugs Global Market Report 2025 – By Therapeutic Class (Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics), By Type of Syndrome (Refractory Cytopenia With Multilineage Dysplasia, Refra...

View Report

Myelodysplastic Syndrome Drugs Global Market Report 2025 – By Therapeutic Class (Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics), By Type of Syndrome (Refractory Cytopenia With Multilineage Dysplasia, Refra...

View Report

Chronic Myeloid Leukemia Treatment Global Market Report 2025 – By Type (Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy, Stem Cell Transplant), By Route of Administration (Oral, Parenteral, Other Route of ...

View Report

Blood Cancer Drugs Global Market Report 2025 – By Blood Cancer Type (Leukemia, Lymphoma), By Drugs (Rituxan/Mabthera (Rituximab), Gleevec/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotin...

View Report

Chronic Myeloid Leukemia Treatment Global Market Report 2025 – By Type (Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy, Stem Cell Transplant), By Route of Administration (Oral, Parenteral, Other Route of ...

View Report

Frequently Asked Questions

Multiple myeloma drugs refer to medications utilized to treat multiple myeloma and cancer-impacting plasma cells (white blood cells found in the bone marrow). These drugs are employed to address bone-related issues such as myeloma, pamidronate (Aredia), and zoledronic acid (Zometa) in an individual. For further insights on this market, request a sample here

The market major growth driver - Soaring Prevalence Of Hematological Cancer Fuels Expansion. For further insights on this market, request a sample here

The multiple myeloma drugs market size has grown strongly in recent years. It will grow from $21.84 billion in 2024 to $23.03 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to improved diagnosis, clinical trials success, understanding of disease biology, healthcare infrastructure improvements, patient advocacy, and awareness The multiple myeloma drugs market size is expected to see strong growth in the next few years. It will grow to " $29.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to immunotherapy innovations, targeted therapies expansion, liquid biopsy applications, the emergence of car-t cell therapy, and biomarker discovery. Major trends in the forecast period include long-term survivorship focus, exploration of epigenetic therapies, expanded role of telemedicine, expanded access to novel therapies, and sustainability in myeloma care. For further insights on this market, request a sample here

The multiple myeloma drugs market covered in this report is segmented –
1) By Drug Type: Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types
2) By Therapy: Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End-User: Men, Women Subsegments:
1) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide
2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib
3) By Histone Deacetylase Inhibitors: Panobinostat, Romidepsin
4) By Monoclonal Antibody Drugs: Daratumumab, Elotuzumab, Isatuximab
5) By Steroids: Dexamethasone, Prednisone
6) By Other Drug Types: Alkylating Agents, Antimetabolites, New Experimental Drugs For further insights on this market, request a sample here

North America was the largest region in the multiple myeloma drugs market in 2024. The regions covered in the multiple myeloma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the multiple myeloma drugs market include Pfizer Inc., Johnson & Johnson Pvt. Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG., Roche Holding AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc, Amgen Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company, Daiichi Sankyo Co. Ltd., Lonza Group AG, Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Biotest AG, Onyx Pharmaceuticals Inc., PharmaMar SA, Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., Oncopetides AB . For further insights on this market, request a sample here.

Major trends in this market include Janssen Biotech Introduced A Groundbreaking Car T-Cell Therapy. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Multiple Myeloma Drugs Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon